Last updated: February 20, 2026
What is the Drug Associated with NDC 51672-1377?
The National Drug Code (NDC) 51672-1377 corresponds to Repatha (evolocumab), a monoclonal antibody used as a lipid-lowering agent. Repatha targets proprotein convertase subtilisin/kexin type 9 (PCSK9), and is approved for the treatment of heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease (ASCVD) as an adjunct to diet, statins, and other lipid-lowering therapies.
Market Overview
Repatha entered the lipid-lowering market in 2015, competing primarily against Amgen's other PCSK9 inhibitor, Praluent (alirocumab), as well as established statins and emerging therapies like inclisiran. The global hypercholesterolemia treatment market was valued at approximately USD 7.6 billion in 2022, with PCSK9 inhibitors accounting for around 25% of the segment.
Key Market Drivers
- Rising prevalence of cardiovascular disease globally.
- Slow but increasing penetration of PCSK9 inhibitors.
- Growing adoption in patient populations intolerant to statins.
- Increasing approval for broader indications, including familial hypercholesterolemia.
Competitive Landscape
| Drug |
Manufacturer |
Approval Year |
Indications |
Estimated 2022 Sales (USD) |
Market Share (PCSK9 class) |
| Repatha (evolocumab) |
Amgen |
2015 |
Heterozygous, homozygous FH, ASCVD |
$1.7 billion |
60% |
| Praluent (alirocumab) |
Sanofi/Regeneron |
2015 |
Similar indications |
$400 million |
25% |
| Inclisiran |
Novartis |
2020 (US) |
Adjunct to diet for hyperlipidemia |
Not yet significant |
5% |
Price Trends and Projections
Current Pricing
- List Price: Approximately USD 14,100 per year for a typical maintenance dose (1 injection every 2 weeks, or 26 doses annually).
- Net Price: Estimated to be around USD 7,000–USD 10,000 after discounts, rebates, and payor negotiations.
Price Drivers
- Increased competition from biosimilars or other PCSK9 inhibitors.
- Payer pressure to reduce drug costs due to high pricing.
- Patient access programs reducing out-of-pocket costs.
- Federal and state policy shifts towards value-based pricing.
Future Price Projections (2023–2028)
| Year |
Estimated Average Price (USD) |
Notes |
| 2023 |
$13,500 – USD 14,000 |
Current list price range, slight reduction expected due to payer pressure |
| 2024 |
$12,800 – USD 13,500 |
Growth of biosimilar competition may influence prices |
| 2025 |
$12,000 – USD 13,000 |
Potential price stabilization amid new entrants |
| 2026 |
$11,500 – USD 12,500 |
Cost-containment negotiations intensify |
| 2027 |
$11,000 – USD 12,000 |
Expansion into broader indications could impact pricing |
| 2028 |
$10,500 – USD 11,500 |
Increased biosimilar pool and value-based models |
Factors Influencing Price Trends
- Entry of biosimilars or generic alternatives could pressure prices downward.
- Shifts to value-based contracts may tie reimbursement to clinical outcomes.
- Policy initiatives targeting drug affordability may cap list prices.
- Market penetration and switching rates from other lipid therapies affect sales volume and pricing.
Market Challenges
- High treatment costs limit access, especially in low- and middle-income countries.
- Physician and patient acceptance is influenced by administration route (subcutaneous injection) and cost.
- Regulatory scrutiny over high-cost specialty drugs may lead to reimbursement restrictions.
Growth Opportunities
- Expansion into emerging markets, where lipid management is evolving.
- Broader understanding of PCSK9 inhibitors' benefits may drive off-label or expanded indications.
- Development of oral or alternative delivery formats could influence market share.
Summary
Repatha maintains a dominant position among PCSK9 inhibitors but faces ongoing pricing and competitive pressures. The average annual cost remains high, although discounts and market dynamics are expected to lower net prices gradually over the next five years. The entry of biosimilars and alternative drugs could accelerate pricing adjustments, affecting both revenues and market share.
Key Takeaways
- Repatha's current list price is about USD 14,100 per year, with net prices likely below USD 10,000.
- The drug holds approximately 60% of the PCSK9 inhibitor market, with sales around USD 1.7 billion in 2022.
- Price projections suggest a gradual decrease, reaching around USD 10,500–USD 11,500 by 2028.
- Market growth is driven by rising cardiovascular disease prevalence and expanding indications.
- Competitive pressures, biosimilar entry, and policy changes will influence future pricing trajectories.
FAQs
-
What factors most influence Repatha pricing?
Competition from biosimilars, payer negotiations, regulatory policies, and market dynamics.
-
How does Repatha compare price-wise to similar drugs?
Repatha's list price is higher than Praluent, but both remain expensive with similar pricing structures.
-
Are biosimilars likely to enter the Repatha market soon?
No biosimilar for evolocumab has been approved as of 2023, but future entries are anticipated, affecting future prices.
-
What are the main barriers to broader adoption?
Cost, administration route, patient eligibility, and reimbursement restrictions.
-
How might expanded indications impact pricing?
Broader use may sustain or slightly elevate prices if payers agree to higher reimbursement, but increased volume could enable discounts.
References
[1] IQVIA Institute. (2022). The Global Use of Medicine in 2022. IQVIA.
[2] U.S. Food and Drug Administration. (2015). FDA approves Repatha to treat certain patients with high cholesterol.
[3] Amgen. (2022). Repatha (evolocumab) prescribing information.
[4] Bloomberg Industry Research. (2023). Hyperlipidemia Market Report.
